Volume 6, Issue 2, June 2020, Page: 52-55
Possible Treatment for the Arresting of Progression of Parkinson’s Disease from Bovine Milk
Jesus’ Christus, Research and Development BioLogistics Limited Liability Company, Ames, USA
Michael Arden Madson, Research and Development BioLogistics Limited Liability Company, Ames, USA
Received: Aug. 26, 2019;       Accepted: Oct. 14, 2019;       Published: May 28, 2020
DOI: 10.11648/j.jfmhc.20200602.14      View  58      Downloads  16
Abstract
An approach to study Ca+2 channel function using bovine milk component or a product (s) of milk components and NaBH4 in NH4OH. The successful study of these molecules could lead to their use in the treatment of Parkinson’s disease or could lead to the use of bovine milk itself as a treatment for this disease. Bovine milk, a source of two molecules and itself, to be used to possibly block the progression of Parkinson’s disease (PD) is reported. The structures of these molecules were established by ESI-MS and API-MS. There is ESI-MS support for the milk component and its product upon treatment with NaBH4 in NH4OH. A mechanism for the possible rescue of Ca+2 channel function is proposed to include a Tyr-Asn (Asp) dipeptide requirement in calcium channels and that it requires the incorporation of N-acetamido neuraminic acid, and SO4- residues as well, for the restoration of calcium channel function. If one or both molecules effectively rescue Ca+2 channel function, an inexpensive treatment of Parkinson’s disease could be available by either simply drinking milk or a treatment could be available via a simple process using bovine milk as its source. A possible treatment of PD, because of the projected low cost, would be available to those less fortunate in the third world.
Keywords
Bovine Milk Component, NaBH4/NH4OH Treatment, Mass Spectrometry, Parkinson’s Disease, Proposed Mechanism of Ca+2 Channel Function
To cite this article
Jesus’ Christus, Michael Arden Madson, Possible Treatment for the Arresting of Progression of Parkinson’s Disease from Bovine Milk, Journal of Family Medicine and Health Care. Vol. 6, No. 2, 2020, pp. 52-55. doi: 10.11648/j.jfmhc.20200602.14
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Pasternak, B.; Svanström, H.; Nielsen, N.; Fugger, L.; Melbye, M.; Hviid, A.; Use of Calcium Channel Blockers and Parkinson’s Disease American Journal of Epidemiology, Volume 175 (7) 627–635 (2012).
[2]
Di Pasquale, E.; Fantini, J.; Chahinian, H.; Maresca, M.; Taïeb, N.; Yahi, N.; GM3 rescue Altered Ion Channel Formation by the Parkinson's-Disease-Linked E46K Mutant of α-Synuclein Is Corrected by GM3 but Not by GM1 Gangliosides J. of Molecular Biology 397, (1) 202-218 (2010).
[3]
Kohno, T.; Kim, J.; Kobayashi, K.; Kodera, Y.; Maeda, T.; Sato, K. Three-Dimensional Structure in Solution of the Calcium Channel Blocker omega-Conotoxin MVIIA Biochemistry 10256-10265 (1995).
[4]
Snail venom toxins Adams, M.; Myers, R.; Imperial, J.; Olivera, B. Toxityping rat brain calcium channels with ῳ-toxins from spider and cone snail toxins Biochemistry 32 12566-12570 (1993).
[5]
Olivera, B.; Gray, W.; Zeikus, R.; McIntosh, J.; Varga, J.; Rivier, J.; de Santos, V.; Cruz, L.; Peptide neurotoxins from fish-hunting cone snails Science 230 (4732) 1338-1343 (1985).
[6]
Christus, J.; Madson, M.; Possible Treatment of Mycobacterium Lepramatous with Bovine Milk World Journal of Food Science and Technology 2 (3) 55-61 (2018).
[7]
Madson, M.; Method of testing for a milk trisaccharide US 8,993,226 B2 (2015).
[8]
Haniu, M.; Horan, T.; Spahr, C.; Hui, J.; Fan, W.; Chen, C.; Richards, W.; Lu, H.; Human Dickkopf-1 (huDKK1) protein: Characterization of glycosylation and determination of disulfide linkages in the two cysteine-rich domains Protein Science (2011).
[9]
McClerkey, E.; Fox, A.; Feldman, D.; Cruz, L.; Olivero, B.; Tsein, R.; Yoshikami, D.; Omega-contoxin: direct and persistent blockade of specific types of calcium channels in neurons not muscle Proceedings. of the National Academy of Science 84 (2) 4327-4331 (1987).
[10]
Hirning, L.; Fox, A.; McClerkey, E.; Boldomero, M.; Stanley, xx.; Dominant role of N-type Ca+2 channels in evoking release of norepinephrine from sympathetic neurons Science 239 (4835) 57-61 (1988).
[11]
Kin, L.; Yishikami, D.; A venom peptide with a novel presynaptic blocking action Nature 308 (5956) 282-284 (1984).
[12]
Gerwig, G.; Hocking, H.; Stocklin, R.; Kamerling, J.; Boelens, R.; Glycosylation of conotoxins. Marine drugs 11 (3) 632-642 (2013).
[13]
Madson, M.; Method of manufacturing MeOH, formaldehyde, formic acid and ammonium pentaborate tetrahydrate US 8,685,335 B2 (2014).
[14]
Madson, M.; Method of discerning substitution of carbohydrate esters US 9,726,671 B2 (2017) Madson, M.; (2017).
[15]
Christus, J.; Madson, M.; Preparation of Possible P Selectin Inhibitor from Bovine Thyroglobulin, (di-hydrido) Sulfo Hydrate 1,5 Anhydro L-fucitol accepted for publication World Journal of Food Science and Technology (2019).
Browse journals by subject